Charissa Y. Chang, Ashwani K. Singal, Sri V. Ganeshan, Thomas D. Schiano, Robert Lookstein, Sukru Emre – 29 October 2007 – Recurrent venous thrombosis following liver transplantation for Budd‐Chiari syndrome is common, particularly in the setting of an underlying myeloproliferative disorder. We describe a patient who developed refractory ascites due to portal vein thrombosis following liver transplantation for Budd‐Chiari syndrome in the setting of paroxysmal nocturnal hemoglobinuria.

Silvina Yantorno, Federico Villamil – 29 October 2007

Michael L. Volk, Jose C. Hernandez, Anna S. Lok, Jorge A. Marrero – 29 October 2007 – The benefit of liver transplantation (LT) is determined not only by the severity of illness, but also by the likelihood of posttransplantation survival. Current models are unable to accurately predict which patients will have the best posttransplant survival. We hypothesized that the Charlson Comorbidity Index (CCI), which includes nine comorbidities, could be used to predict survival after LT. We performed a retrospective study of 624 patients undergoing LT, with a median follow‐up time of 4.3 yr.

Andrea DiMartini – 29 October 2007

Thomas P. Beresford – 29 October 2007

Vincenzo Mazzaferro – 29 October 2007

Alberto Rubio‐Tapia, Joseph A. Murray – 29 October 2007 – Celiac disease is a common (1% prevalence) chronic immune‐mediated disorder of the small intestine induced by dietary wheat, barley, and rye. Several hepatic disorders have been described in association with celiac disease. Isolated hypertransaminasemia with nonspecific histologic changes in a liver biopsy is the commonest hepatic presentation of celiac disease. A gluten‐free diet normalizes liver enzymes and histologic changes in most patients.

Paula Bonorino, Vincent Leroy, Tania Dufeu‐Duchesne, Stefania Tongiani‐Dashan, Nathalie Sturm, Martine Pernollet, Eric Vivier, Jean‐Pierre Zarski, Patrice N. Marche, Evelyne Jouvin‐Marche – 29 October 2007 – CD8+ T cells represent a sizable component of the liver inflammatory infiltrate in chronic hepatitis C and are thought to contribute to immune‐mediated tissue injury.

Bruce Wang, Brian M. Dolinski, Noriko Kikuchi, Diane R. Leone, Marion G. Peters, Paul H. Weinreb, Shelia M. Violette, D. Montgomery Bissell – 29 October 2007 – Acute biliary obstruction leads to periductal myofibroblasts and fibrosis, the origin of which is uncertain. Our study provides new information on this question in mice and humans. We show that bile duct obstruction induces a striking increase in cholangiocyte αvβ6 integrin and that expression of this integrin is directly linked to fibrogenesis through activation of transforming growth factor beta (TGF‐β).

Norio Akuta, Fumitaka Suzuki, Yusuke Kawamura, Hiromi Yatsuji, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada – 29 October 2007 – We showed previously that amino acid (aa) substitutions in hepatitis C virus core region (HCV‐CR) are negative predictors of virologic response to pegylated interferon (IFN) plus ribavirin therapy. HCV‐CR induces hepatocellular carcinoma in transgenic mice, but the clinical impact is still unclear.